Welcome to our dedicated page for Adocia news (Ticker: ADOCY), a resource for investors and traders seeking the latest updates and insights on Adocia stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adocia's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adocia's position in the market.
Adocia, a clinical-stage biopharmaceutical company based in Lyon, France, has confirmed its eligibility for the PEA-PME stock savings tax regime. This eligibility, effective from March 6, 2014, is based on the company's market capitalization being under one billion euros, having less than 5,000 employees, and an annual turnover below 1.5 billion euros. Adocia specializes in developing therapeutic solutions for diabetes and metabolic diseases and holds over 25 patent families.
Adocia has scheduled its annual shareholders’ meeting (AGM) for June 28, 2022, at 10:00 am in Paris. The notice has been published in the French Bulletin des Annonces Légales Obligatoires, detailing the agenda and proposed resolutions. Shareholders must register their shares two business days prior to the meeting to participate. They can submit questions to the Board of Directors in writing, with specific instructions provided. Adocia specializes in therapeutic solutions for diabetes and holds over 25 patent families.
Adocia (Euronext: ADOC) reported its first quarter 2022 results with revenues reaching
Adocia has initiated the CT046-ADO05 clinical trial with the first patient treated. The Last Patient Last Visit is anticipated by
Adocia has initiated a Phase 3 clinical trial for its BioChaperone® Lispro insulin, enrolling 1,300 diabetes patients across 100 centers in China. This marks a significant milestone, triggering a $5 million payment from Tonghua Dongbao to Adocia, with potential future payments totaling $30 million linked to further developments. Additionally, the agreement includes double-digit royalties from sales in territories encompassing over 200 million diabetes patients. The Chinese insulin market is projected to grow from $3.5 billion in 2018 to $5 billion by 2025.
Adocia, a clinical-stage biopharmaceutical company, filed its 2021 Universal Reference Document with the AMF on April 21, 2022. This document includes the annual financial report, the Management Report, and the corporate governance report. Adocia specializes in innovative treatments for diabetes and metabolic diseases, holding over 25 patent families, and is recognized for its proprietary technologies like BioChaperone® and AdOral®. For further details, the document can be accessed on Adocia's website and the AMF's site.
Adocia, a clinical-stage biopharmaceutical company focused on diabetes treatment, reported its 2021 financial results with significant advancements. The company had a cash position of €15.2 million at the end of 2021, improving to €28 million by March 2022. Key developments included the approval to enter Phase 3 for BioChaperone® Lispro in China and the start of clinical studies for two new products. Despite a net loss of €22.8 million, revenue increased to €1.4 million from licensing contracts. Promising projects are underway for 2022 with anticipated milestone payments of up to $85 million.
FAQ
What is the market cap of Adocia (ADOCY)?
